# STIC Biotechnology Systems Branch

# RAW SEQUENCE LISTING
## ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: _10/560,790_

Source: _1FWP_

Date Processed by STIC: _12/27/05_

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:
1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY
FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221


TO **REDUCE** ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER VERSION 4.2.2 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

**http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm**


Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.
Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.
Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (**<http://www.uspto.gov/ebc/efs/downloads/documents.htm>** , EFS Submission User Manual - ePAVE)
2. **U.S. Postal Service:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. **Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):** U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street. Alexandria, VA 22314

Revised 01/24/05

# Raw Sequence Listing Error Summary

| ERROR DETECTED | SUGGESTED CORRECTION | SERIAL NUMBER: _10/560,790_ |

**ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE**

1 _____ Wrapped Nucleics
Wrapped Aminos
The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor **after** creating it. Please adjust your right margin to .3; this will prevent "wrapping."

2 _____ Invalid Line Length
The rules require that a line **not exceed** 72 characters in length. This includes white spaces.

3 _____ Misaligned Amino
Numbering
The numbering under each 5th amino acid is misaligned. Do **not** use tab codes between numbers; use **space characters**, instead.

4 _____ Non-ASCII
The submitted file was **not** saved in ASCII(DOS) text, as **required** by the Sequence Rules. **Please ensure your subsequent submission is saved in ASCII text.**

5 _____ Variable Length
Sequence(s) _____ contain n's or Xaa's representing more than one residue. **Per Sequence Rules, each n or Xaa can only represent a single residue.** Please present the **maximum** number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.

6 _____ PatentIn 2.0
"bug"
A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. **This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.**

7 _____ Skipped Sequences
(OLD RULES)
Sequence(s) _____ missing. If intentional, please insert the following lines for **each** skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
(i)        SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to **include** the skipped sequences.

8 _____ Skipped Sequences
(NEW RULES)
Sequence(s) _____ missing. If **intentional**, please insert the following lines for **each** skipped sequence.
<210> sequence id number
<400> sequence id number
000

9 _____ Use of n's or Xaa's
(NEW RULES)
Use of n's and/or Xaa's have been detected in the Sequence Listing.
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.

10 _____ Invalid <213>
Response
Per 1.823 of Sequence Rules, the only **valid** <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is **required** when <213> response is Unknown or is Artificial Sequence

11 _____ Use of <220>
Sequence(s) _____ missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32)   (Sec. 1.823 of Sequence Rules)

12 _____ PatentIn 2.0
"bug"
Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

13 _____ Misuse of n/Xaa
"n" can **only** represent a single <u>nucleotide</u>; "Xaa" can **only** represent a single <u>amino acid</u>

**PCT**

RAW SEQUENCE LISTING                         DATE: 12/27/2005
PATENT APPLICATION: **US/10/560,790**        TIME: 09:11:38

Input Set : **A:\Seq. Listing.txt**
Output Set: **N:\CRF4\12272005\J560790.raw**

```
     3 <110> APPLICANT: GHOSH, Peter
     5 <120> TITLE OF INVENTION: Connective tissue derived polypeptides
     7 <130> FILE REFERENCE: 10682.0010USWO
C--> 9 <140> CURRENT APPLICATION NUMBER: US/10/560,790
    10 <141> CURRENT FILING DATE: 2005-12-15
    12 <150> PRIOR APPLICATION NUMBER: PCT/AU2004/000788
    13 <151> PRIOR FILING DATE: 2004-06-17
    15 <150> PRIOR APPLICATION NUMBER: AU2003903037
    16 <151> PRIOR FILING DATE: 2003-06-17
    18 <160> NUMBER OF SEQ ID NOS: 19
    20 <170> SOFTWARE: PatentIn version 3.1
```

*pp 3-5*

**ERRORED SEQUENCES**

*Does Not Comply*
*Corrected Diskette Needed*

```
   952 <210> SEQ ID NO: 19
   953 <211> LENGTH: 921
   954 <212> TYPE: PRT
   955 <213> ORGANISM: mouse alpha (IX) chain precursor
   957 <400> SEQUENCE: 19
   959 Met Lys Asn Phe Trp Lys Ile Ser Val Phe Phe Cys Val Cys Ser Cys
   960 1               5                   10                  15
   963 Leu Gly Pro Trp Val Ser Ala Thr Leu Lys Arg Arg Ala Arg Phe Pro
   964             20                  25                  30
   967 Ala Asn Ser Ile Ser Asn Gly Gly Ser Glu Leu Cys Pro Lys Ile Arg
   968         35                  40                  45
   971 Ile Gly Gln Asp Asp Leu Pro Gly Phe Asp Leu Ile Ser Gln Phe Gln
   972     50                  55                  60
   975 Ile Glu Lys Ala Ala Ser Arg Arg Thr Ile Gln Arg Val Val Gly Ser
   976 65                  70                  75                  80
   979 Thr Ala Leu Gln Val Ala Tyr Lys Leu Gly Ser Asn Val Asp Phe Arg
   980             85                  90                  95
   983 Ile Pro Thr Arg His Leu Tyr Pro Ser Gly Leu Pro Glu Glu Tyr Ser
   984             100                 105                 110
   987 Phe Leu Thr Thr Phe Arg Met Thr Gly Ser Thr Leu Glu Lys His Trp
   988             115                 120                 125
   991 Asn Ile Trp Gln Ile Gln Asp Ser Ala Gly Arg Glu Gln Val Gly Val
   992     130                 135                 140
   995 Lys Ile Asn Gly Gln Thr Lys Ser Val Ala Phe Ser Tyr Lys Gly Leu
   996 145                 150                 155                 160
   999 Asp Gly Ser Leu Gln Thr Ala Ala Phe Leu Asn Leu Pro Ser Leu Phe
  1000             165                 170                 175
  1003 Asp Ser Arg Trp His Lys Leu Met Ile Gly Val Glu Arg Thr Ser Ala
```

```
1004               180                 185                 190
1007 Thr Leu Phe Ile Asp Cys Ile Arg Ile Glu Ser Leu Pro Ile Lys Pro
1008           195                 200                 205
1011 Arg Gly Gln Ile Asp Ala Asp Gly Phe Ala Val Leu Gly Lys Leu Val
1012      210                 215                 220
1015 Asp Asn Pro Gln Val Ser Val Pro Phe Glu Leu Gln Trp Met Leu Ile
1016 225                 230                 235                 240
1019 His Cys Asp Pro Leu Arg Pro Arg Arg Glu Thr Cys His Glu Leu Pro
1020               245                 250                 255
1023 Ile Arg Ile Thr Thr Ser Gln Thr Thr Asp Glu Arg Gly Pro Pro Gly
1024           260                 265                 270
1027 Glu Gln Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Val Pro Gly Ile
1028      275                 280                 285
1031 Asp Gly Ile Asp Gly Asp Arg Gly Pro Lys Gly Pro Pro Gly Pro Pro
1032      290                 295                 300
1035 Gly Pro Pro Gly Asp Pro Gly Lys Pro Gly Ala Pro Gly Lys Pro Gly
1036 305                 310                 315                 320
1039 Thr Pro Gly Ala Asp Gly Leu Thr Gly Pro Asp Gly Ser Pro Gly Ser
1040           325                 330                 335
1043 Val Gly Pro Arg Gly Gln Lys Gly Glu Pro Gly Val Pro Gly Ser Arg
1044           340                 345                 350
1047 Gly Phe Pro Gly Arg Gly Ile Pro Gly Pro Pro Gly Pro Pro Gly Thr
1048      355                 360                 365
1051 Thr Gly Leu Pro Gly Glu Leu Gly Arg Val Gly Pro Ile Gly Asp Pro
1052      370                 375                 380
1055 Gly Lys Arg Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Ser Gly
1056 385                 390                 395                 400
1059 Thr Ile Gly Phe His Asp Gly Asp Pro Leu Cys Pro Asn Ser Cys Pro
1060           405                 410                 415
1063 Pro Gly Arg Ser Gly Tyr Pro Gly Leu Pro Gly Met Arg Gly His Lys
1064           420                 425                 430
1067 Gly Ala Lys Gly Glu Ile Gly Glu Pro Gly Arg Gln Gly His Lys Gly
1068      435                 440                 445
1071 Glu Glu Gly Asp Gln Gly Glu Leu Gly Glu Val Gly Ala Gln Gly Pro
1072      450                 455                 460
1075 Pro Gly Pro Gln Gly Leu Arg Gly Ile Thr Gly Ile Val Gly Asp Lys
1076 465                 470                 475                 480
1079 Gly Glu Lys Gly Ala Arg Gly Phe Asp Gly Glu Pro Gly Pro Gln Gly
1080           485                 490                 495
1083 Ile Pro Gly Ala Ala Gly Asp Gln Gly Gln Arg Gly Pro Pro Gly Glu
1084           500                 505                 510
1087 Thr Gly Pro Lys Gly Asp Arg Gly Ile Gln Gly Ser Arg Gly Ile Pro
1088           515                 520                 525
1091 Gly Ser Pro Gly Pro Lys Gly Asp Thr Gly Leu Pro Gly Val Asp Gly
1092      530                 535                 540
1095 Arg Asp Gly Ile Pro Gly Met Pro Gly Thr Lys Gly Glu Ala Gly Lys
1096 545                 550                 555                 560
1099 Pro Gly Pro Pro Gly Asp Val Gly Leu Gln Gly Leu Pro Gly Val Pro
1100           565                 570                 575
```

RAW SEQUENCE LISTING
PATENT APPLICATION:  US/10/560,790

DATE: 12/27/2005
TIME: 09:11:38

Input Set : **A:\Seq. Listing.txt**
Output Set: **N:\CRF4\12272005\J560790.raw**

```
1103 Gly Ile Pro Gly Ala Lys Gly Val Ala Gly Glu Lys Gly Asn Thr Gly
1104             580             585             590
1107 Ala Pro Gly Lys Pro Gly Gln Leu Gly Ser Ser Gly Lys Pro Gly Gln
1108             595             600             605
1111 Gln Gly Pro Pro Gly Glu Val Gly Pro Arg Gly Pro Arg Gly Leu Pro
1112      610             615             620
1115 Gly Ser Arg Gly Pro Val Gly Pro Glu Gly Ser Pro Gly Ile Pro Gly
1116 625             630             635             640
1119 Lys Leu Gly Ser Val Gly Ser Pro Gly Leu Pro Gly Leu Pro Gly Pro
1120             645             650             655
1123 Pro Gly Leu Pro Gly Met Lys Gly Asp Arg Gly Val Phe Gly Glu Pro
1124             660             665             670
1127 Gly Pro Lys Gly Glu Gln Gly Ala Ser Gly Glu Glu Gly Glu Ala Gly
1128             675             680             685
1131 Ala Arg Gly Asp Leu Gly Asp Met Gly Gln Pro Gly Pro Lys Gly Ser
1132             690             695             700
1135 Val Gly Asn Pro Gly Glu Pro Gly Leu Arg Gly Pro Glu Gly Ile Arg
1136 705             710             715             720
1139 Gly Leu Pro Gly Val Glu Gly Pro Arg Gly Pro Pro Gly Pro Arg Gly
1140             725             730             735
1143 Met Gln Gly Glu Gln Gly Ala Thr Gly Leu Pro Gly Ile Gln Gly Pro
1144             740             745             750
1147 Pro Gly Arg Ala Pro Thr Asp Gln His Ile Lys Gln Val Cys Met Arg
1148             755             760             765
1151 Val Val Gln Glu His Phe Val Glu Met Ala Ala Ser Leu Lys Arg Pro
1152      770             775             780
1155 Asp Thr Gly Ala Ser Gly Leu Pro Gly Arg Pro Gly Pro Pro Gly Pro
1156 785             790             795             800
1159 Pro Gly Pro Pro Gly Glu Asn Gly Phe Pro Gly Gln Met Gly Ile Arg
1160             805             810             815
1163 Gly Leu Pro Gly Ile Lys Gly Pro Pro Gly Ala Leu Gly Leu Arg Gly
1164             820             825             830
1167 Pro Lys Gly Asp Leu Gly Glu Lys Gly Glu Arg Gly Pro Pro Gly Arg
1168             835             840             845
1171 Gly Pro Lys Gly Leu Pro Gly Ala Ile Gly Leu Pro Gly Asp Pro Gly
1172 850             855             860
1175 Pro Ala Ser Tyr Gly Lys Asn Gly Arg Asp Gly Glu Gln Gly Pro Pro
1176 865             870             875             880
1179 Gly Val Ala Gly Ile Pro Gly Val Pro Gly Pro Pro Gly Pro Pro Gly
1180             885             890             895
1183 Pro Pro Gly Phe Cys Glu Pro Ala Ser Cys Thr Leu Gln Ser Gly Gln
1184             900             905             910
1187 Arg Ala Phe Ser Lys Gly Pro Asp Lys
1188      915             920
E--> 1195 4
```

*delete*

```
<210>  1
<211>  187
<212>  PRT
<213>  Partial sequence of bovine NC4 domain of Type IX collagen alpha 1 chain

<400>  1
```

*see item 10 on Error Summary Sheet*

*This would be a sufficient <213> response*

```
<210>  2
<211>  9
<212>  PRT
<213>  Type IX collagen alpha 1 chain peptide
```

FYI

The type of errors shown exist throughout
the Sequence Listing. Please check subsequent
sequences for similar errors.

L:9 M:270 C: Current Application Number differs, Replaced Current Application Number
L:1195 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:19